Skip to main content
. 2022 Oct 27;61(22):2568–2578. doi: 10.1021/acs.biochem.2c00449

Figure 2.

Figure 2

Terminal (A) and internal (B) cross-linking strategies by CuAAC to pre-shape a linear ssDNA as a substrate (dC-containing oligo) and as an inhibitor of A3BCTD (dZ-containing oligo). (C) Alkyne (Y) and azide (dRN3) modifications used in the sequence for terminal cross-linking strategy. (D) Alkyne (dUE) and azide (dAN3) modifications used for internal cross-linking strategy.